Sprint Bioscience AB (publ) (STO:SPRINT)
Sweden · Delayed Price · Currency is SEK 3.410
+0.180 (5.57%)
Aug 13, 2026, 5:29 PM CET
Sprint Bioscience AB Market Cap
Sprint Bioscience AB has a market cap or net worth of 340.82 million as of August 13, 2026. Its market cap has increased by 443.77% in one year.
Market Cap
340.82M
Enterprise Value
232.49M
Revenue
153.28M
Ranking
n/a
PE Ratio
3.92
Stock Price
3.41
ChartMarket Cap Chart
Since November 7, 2014, Sprint Bioscience AB's market cap has increased from 62.49M to 340.82M, an increase of 445.35%. That is a compound annual growth rate of 15.50%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 12, 2026 | 340.82M | 119.73% |
| Dec 30, 2025 | 155.11M | 40.43% |
| Dec 30, 2024 | 110.46M | -8.82% |
| Dec 29, 2023 | 121.14M | 449.78% |
| Dec 30, 2022 | 22.03M | -88.47% |
| Dec 30, 2021 | 191.05M | 17.26% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Oncopeptides AB | 630.09M |
| FluoGuide | 505.19M |
| Corline Biomedical AB | 471.70M |
| Cantargia AB | 448.74M |
| Mendus AB | 412.97M |
| Intervacc AB | 411.70M |
| Isofol Medical AB | 279.47M |
| IRLAB Therapeutics AB | 227.53M |